
Anticoagulants have been the mainstay of therapy for the long-term and acute prevention and treatment of various types of thromboembolic disorders. The prevention of thromboembolic stroke among patients with persistent atrial fibrillation (AF) has been one of the main indications for oral anticoagulation therapy. At least 2.6 million people are living with atrial fibrillation, and it is estimated to reach 12 million people by the year 2050, states American Heath Health Association. Additionally, anticoagulants are indicated in, and are firmly prescribed for the prevention and treatment of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT). As such, unfractionated heparin, vitamin K antagonists (such as warfarin), direct thrombin inhibitors (such as dabigatran and argatroban) and factor Xa inhibitors (e.g., fondaparinux, apixaban and rivaroxaban) become crucial for the prevention and treatment of these disorders. These actionable insights are in line with the report, titled, "Anticoagulants Market—Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026," which has been freshly incorporated in Market Research Hub's (MRH) ever-expanding repository. The introduction of novel oral anticoagulants (NOACs) to the anticoagulants market have attenuated a few of the health care system burdens linked with outpatient warfarin management. NOACs are efficacious as compared to the conventional therapies such as warfarin, which is anticipated to propel the growth of anticoagulants market.